首页 > 最新文献

Gynecology and reproductive endocrinology最新文献

英文 中文
Implementation of a restrictive blood transfusion protocol in a gynecologic oncology service. 在妇科肿瘤服务中实施限制性输血方案。
Pub Date : 2019-01-01 DOI: 10.35841/2591-7994.3.1-5
Jaron Mark, Sarah Lynam, Kayla Morrell, Kevin Eng, Kristen Starbuck, J Brian Szender, Emese Zsiros, Peter J Frederick

Objectives: The purpose of this study was to evaluate the impact of a restrictive blood transfusion protocol in a postoperative gynecologic oncology population. The primary objective was the rate of blood transfusions after surgery before and after implementation of a restrictive transfusion protocol (from July 1st 2011 to December 30th 2016). Secondary outcomes were patient morbidity and included rates of surgical site infection, pneumonia, sepsis, unplanned intubation, prolonged ventilator use, renal insufficiency, acute renal failure, urinary tract infection, cerebral vascular accident, cardiac complications, venous thromboembolism, and death within 30 days of surgery, readmissions and length of stay.

Methods: A restrictive blood transfusion protocol was implemented by the gynecologic oncology service at a National Comprehensive Cancer Network designated Comprehensive Cancer Center on January 1st, 2014. The restrictive protocol required that no patient receive a blood transfusion for hemoglobin greater than 7.0 g/dL (or hematocrit greater than 21.0%) and that all red blood cells were administered in one unit increments followed by re-evaluation of blood parameters. Exceptions to this protocol were postoperative symptomatic anemia, intraoperative or day of surgery transfusion, active bleeding, postoperative severe sepsis, postoperative active coronary ischemia, and postoperative transfusion after 1.5 liter or greater blood loss.

Results: 1482 patients were identified for this study (755 in the pre-protocol group and 727 in the post-protocol group). Patients treated under the restrictive protocol had decreased rates of red blood cell transfusion (11.0% vs 5.9% p<0.001), superficial surgical site infection (7.7% vs 4.1% p=0.005), deep surgical site infection (2.3% vs 0.7% p=0.02), and median length of stay (3.0 days vs 2.0 days p<0.001).

Conclusions: A restrictive blood transfusion protocol is associated with reductions in the rates of blood transfusions and postoperative morbidity with a 46.8% reduction in superficial surgical site infection and a 69.6% decrease in deep surgical site infection in the gynecologic oncology patient population.

研究目的本研究旨在评估限制性输血方案对妇科肿瘤术后人群的影响。首要目标是限制性输血方案实施前后(2011 年 7 月 1 日至 2016 年 12 月 30 日)的术后输血率。次要结果是患者的发病率,包括手术部位感染、肺炎、脓毒症、意外插管、长时间使用呼吸机、肾功能不全、急性肾衰竭、尿路感染、脑血管意外、心脏并发症、静脉血栓栓塞、术后30天内死亡、再次入院和住院时间:美国国家综合癌症网络指定综合癌症中心的妇科肿瘤服务部门于 2014 年 1 月 1 日开始实施限制性输血方案。该限制性输血方案规定,血红蛋白超过 7.0 g/dL(或血细胞比容超过 21.0%)的患者不得接受输血,所有红细胞均以一个单位为单位递增,然后重新评估血液参数。术后症状性贫血、术中或手术当天输血、活动性出血、术后严重败血症、术后活动性冠状动脉缺血以及术后失血 1.5 升或更多后输血除外:本研究共确定了 1482 名患者(755 名患者属于方案前组,727 名患者属于方案后组)。在限制性方案下接受治疗的患者输注红细胞(11.0% vs 5.9% pvs 4.1% p=0.005)、深部手术部位感染(2.3% vs 0.7% p=0.02)和中位住院时间(3.0 天 vs 2.0 天 p=0.005)的比例均有所下降:在妇科肿瘤患者中,限制性输血方案可降低输血率和术后发病率,浅表手术部位感染率降低了46.8%,深部手术部位感染率降低了69.6%。
{"title":"Implementation of a restrictive blood transfusion protocol in a gynecologic oncology service.","authors":"Jaron Mark, Sarah Lynam, Kayla Morrell, Kevin Eng, Kristen Starbuck, J Brian Szender, Emese Zsiros, Peter J Frederick","doi":"10.35841/2591-7994.3.1-5","DOIUrl":"10.35841/2591-7994.3.1-5","url":null,"abstract":"<p><strong>Objectives: </strong>The purpose of this study was to evaluate the impact of a restrictive blood transfusion protocol in a postoperative gynecologic oncology population. The primary objective was the rate of blood transfusions after surgery before and after implementation of a restrictive transfusion protocol (from July 1<sup>st</sup> 2011 to December 30<sup>th</sup> 2016). Secondary outcomes were patient morbidity and included rates of surgical site infection, pneumonia, sepsis, unplanned intubation, prolonged ventilator use, renal insufficiency, acute renal failure, urinary tract infection, cerebral vascular accident, cardiac complications, venous thromboembolism, and death within 30 days of surgery, readmissions and length of stay.</p><p><strong>Methods: </strong>A restrictive blood transfusion protocol was implemented by the gynecologic oncology service at a National Comprehensive Cancer Network designated Comprehensive Cancer Center on January 1<sup>st</sup>, 2014. The restrictive protocol required that no patient receive a blood transfusion for hemoglobin greater than 7.0 g/dL (or hematocrit greater than 21.0%) and that all red blood cells were administered in one unit increments followed by re-evaluation of blood parameters. Exceptions to this protocol were postoperative symptomatic anemia, intraoperative or day of surgery transfusion, active bleeding, postoperative severe sepsis, postoperative active coronary ischemia, and postoperative transfusion after 1.5 liter or greater blood loss.</p><p><strong>Results: </strong>1482 patients were identified for this study (755 in the pre-protocol group and 727 in the post-protocol group). Patients treated under the restrictive protocol had decreased rates of red blood cell transfusion (11.0% <i>vs</i> 5.9% p<0.001), superficial surgical site infection (7.7% <i>vs</i> 4.1% p=0.005), deep surgical site infection (2.3% <i>vs</i> 0.7% p=0.02), and median length of stay (3.0 days <i>vs</i> 2.0 days p<0.001).</p><p><strong>Conclusions: </strong>A restrictive blood transfusion protocol is associated with reductions in the rates of blood transfusions and postoperative morbidity with a 46.8% reduction in superficial surgical site infection and a 69.6% decrease in deep surgical site infection in the gynecologic oncology patient population.</p>","PeriodicalId":93002,"journal":{"name":"Gynecology and reproductive endocrinology","volume":"3 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299237/pdf/nihms-1029689.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38059606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of follicular fluid concentrations of anti-mullerian hormone, bone morphogenetic protein 15 and transforming growth factor ß1 between modified natural and stimulated in-vitro fertilization cycles. 改良自然和刺激体外受精周期卵泡液中抗苗勒管激素、骨形态发生蛋白15和转化生长因子ß1浓度的比较。
Pub Date : 2019-01-01 DOI: 10.35841/2591-7994.3.12-13
T. Burnik Papler
{"title":"Comparison of follicular fluid concentrations of anti-mullerian hormone, bone morphogenetic protein 15 and transforming growth factor ß1 between modified natural and stimulated in-vitro fertilization cycles.","authors":"T. Burnik Papler","doi":"10.35841/2591-7994.3.12-13","DOIUrl":"https://doi.org/10.35841/2591-7994.3.12-13","url":null,"abstract":"","PeriodicalId":93002,"journal":{"name":"Gynecology and reproductive endocrinology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70031376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Gynecology and reproductive endocrinology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1